Search Results
Your search for ASCO Post,ASCO Post matches 17663 pages
Showing 51 - 100Preoperative Endocrine Therapy for Older Women With Estrogen Receptor–Positive Breast Cancer: Impact on Radiotherapy Decisions
Providing a brief, 90-day course of preoperative endocrine therapy to older women with early-stage, estrogen receptor–positive, invasive breast cancer may significantly alter both patient preferences and physician recommendations regarding adjuvant radiation therapy, according to data presented...
HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies
Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...
ASCO Honors Karen Eubanks Jackson of Sisters Network® Inc. With 2025 Patient Advocate Award
Karen Eubanks Jackson, founder and Chief Executive Officer of Sisters Network® Inc. (SNI), has been named the recipient of the 2025 Patient Advocate Award by ASCO, Conquer Cancer, and the ASCO Foundation. The awards ceremony was held during the 2025 ASCO Annual Meeting. (See a video with Ms....
National Comprehensive Cancer Network Launches NCCN Guidelines Navigator
The National Comprehensive Cancer Network® (NCCN®) has announced a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines® are the recognized standard for clinical decision-making and policy in cancer care and are the...
ASCO Guideline Update Calls for Omission of SLNB in Select Patients With Early-Stage Breast Cancer
ASCO has released a clinical practice guideline update on the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer.1 The update includes recommendations based on findings from trials released after the published guideline in 2017, including data from nine randomized trials...
ACS Study Focuses on Effects of Medicaid Expansion in Low-Income Older Adults With Cancer
A recent study by researchers at the American Cancer Society (ACS) showed that Medicaid expansion was associated with an increase in Medicaid coverage, early-stage cancer diagnoses, and improved 2-year survival among individuals aged 65 or older who were diagnosed with cancer. They believe these...
FDA Approves Label Expansion for Agent Used in Patient Selection for Pre-Taxane Radioligand Therapy
The U.S. Food and Drug Administration (FDA) has approved a label expansion of a kit for the preparation of gallium Ga-68 gozetotide for injection (Illuccix) to include patient selection for radioligand therapy in the pre-taxane setting. The update applies to the imaging agent’s third indication,...
Silence Is Complicity
On January 20, 2025, newly sworn-in President Donald J. Trump signed Executive Order 14151, “Ending Radical and Wasteful Government DEI Programs and Preferencing,”1 effectively eliminating all diversity, equity, and inclusion (DEI) programs, preferences, and activities across the federal...
Role of Mitochondrial Pathways in Melanoma Progression, Treatment Resistance
The most aggressive melanomas may hyperactivate two key processes in mitochondria, according to a novel study, and blocking these pathways with currently available drugs may eliminate melanoma cells, explained investigators. These findings were published by Kim et al in the journal Cancer....
FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-Mutated NSCLC
On June 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway), an antibody-drug conjugate that targets trophoblast cell surface antigen 2 (TROP2), for adults with locally advanced or metastatic EGFR-mutated non–small cell lung cancer...
Cohort Study Finds Genetics of Cardiomyopathy Risk in Cancer Survivors Differ by Age of Onset
The relationship between genetic variants and the risk of late-onset cardiomyopathy remains poorly understood in survivors of childhood cancer despite being otherwise well established. Scientists from St. Jude Children’s Research Hospital have helped address this gap, assessing whether variant...
New Model Predicts Risk of Progression in Early-Stage Classical Hodgkin Lymphoma
The first individualized risk prediction model for adults with early-stage classical Hodgkin lymphoma (cHL) has been developed and validated. According to a report published in NEJM Evidence, the Early-Stage cHL International Prognostic Index (E-HIPI) model estimates 2-year progression-free...
Gut Microbiome May Hold Key to Avoiding Chemotherapy-Related Cardiotoxicity in Patients With Breast Cancer
A healthy gut microbiome prior to chemotherapy could help protect against cardiotoxicity as a result of breast cancer therapy, according to new findings presented by Antoniades et al at the European Society of Cardiology (ESC) Cardio-Oncology 2025 annual conference. Background Cardiotoxicity is a...
Symptom-Detected Breast Cancers May Be Linked to Higher Mortality and Advanced Disease Risk
Whether a patient’s breast cancer was detected through symptoms or routine screening mammography significantly affected their risk for advanced disease or death, according to a study published recently in Radiology: Imaging Cancer. Patients with symptom-detected breast cancer had higher odds of...
ASH 2025 Awardees: Hematologists to Be Honored With Highest Distinctions
The American Society of Hematology (ASH) announced that it will recognize 11 hematologists who have made notable contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, from December 6–9, 2025. The...
How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival
A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....
Establishing Novel Models of Interdisciplinary Care to Improve Survival Outcomes in Patients With Cancer
Internationally renowned for her decades-long pioneering research in pancreatic cancer, in 2024, Diane M. Simeone, MD, left her positions as the Laura and Isaac Perlmutter Professor of Surgery and Pathology; Director, Pancreatic Cancer Center; and Associate Director of the Perlmutter Cancer Center...
Outcomes of Oncologic Extended Resection for Gallbladder Cancer: Results of a Global Analysis
In the United States, approximately 55% of patients with resected gallbladder cancer undergo oncologic surgery without additional systemic treatment. However, as gallbladder cancer progresses to T3 (locally or regionally advanced) or T4 (distant metastasis) disease, the tumor frequently infiltrates ...
FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma
On June 18, the U.S. Food and Drug Administration approved tafasitamab-cxix (Monjuvi), a CD19-directed cytolytic antibody, with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. inMIND Trial Efficacy was evaluated in inMIND (ClinicalTrials.gov identifier...
Study Identifies Key LBCL Traits Tied to Greatest Benefit From CD19 CAR T-Cell Therapy
In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center have identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels of benefit from CD19-targeted chimeric antigen receptor (CAR) T cell therapy. In the study,...
Elevated Cardiac Biomarkers Associated With Increased Cancer Risk
Higher baseline levels of certain cardiac biomarkers were associated with an increased risk of future incidence of cancer, according to findings from a study published in the Journal of the American College of Cardiology: Advances. Higher incidence rates for all cancers were associated with higher ...
Psilocybin May Benefit Patients With Cancer, Major Depressive Disorder
A single dose of psilocybin may provide sustained reductions in depression and anxiety among patients with cancer and major depressive disorder, according to a recent study published by Agrawal et al in Cancer. Patients with cancer often experience depression. Psilocybin is a naturally occurring...
Order of CRC Diagnosis May Influence Survival in Patients With Multiple Malignancies
The order of colorectal cancer diagnosis seems to have a significant impact on outcomes in patients with multiple primary malignancies, according to the results of a study of Surveillance, Epidemiology, and End Results (SEER) Program data. Findings from the study were published in the Journal of...
BRCA Mutations Could Increase Risk of Rare Lymphoma Among Women Who Received Textured Breast Implants During Breast Cancer Treatment
The risk of developing breast implant–associated anaplastic large-cell lymphoma (ALCL) could be higher among women with breast cancer and BRCA1 or BRCA2 mutations who received textured breast implants as part of their postmastectomy reconstructive surgery compared with patients lacking the genetic...
Study Defines Divergent Molecular Pathways in HPV-Associated vs HPV-Independent Sinonasal Cancers
Findings from a comprehensive genome-wide study of sinonasal squamous cell carcinomas demonstrated that human papillomavirus (HPV) can drive tumorigenesis in some cases, and these tumors exhibit similar mutational patterns to those seen in HPV-associated cervical and head and neck squamous cell...
Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations
A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia (AML) and an NPM1 mutation or KMT2A rearrangement. The regimen was also shown to be safe in updated results from ...
Early Results for CAR T-Cell Therapy in Relapsed or Refractory AL Amyloidosis
Initial early results were seen for the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory amyloid light-chain (AL) amyloidosis in the NEXICART-2 trial. This was the first U.S. trial of CAR T-cell therapy for patients with AL amyloidosis, demonstrating...
Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced Breast Cancer: Vepdegestrant vs Fulvestrant
Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with...
Gerhardt Attard, MD, PhD, on a Novel Regimen for Metastatic Castration-Sensitive Prostate Cancer With HRR Alterations
Gerhardt Attard, MD, PhD, of the Cancer Institute, University College London, presents findings from the phase III AMPLITUDE trial, which looked at the combination of niraparib and abiraterone acetate plus prednisone for patients with metastatic castration-sensitive prostate cancer with alterations ...
Colorectal Cancer Screening: CT Colonography vs Stool Testing
Computed tomography (CT) colonography demonstrated greater clinical efficacy and cost savings than stool DNA testing for colorectal cancer screening, according to results of a study published in Radiology. "Among the safe, minimally invasive colorectal cancer screening options, CT colonography is ...
FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable, Locally Advanced Head and Neck Cancer
Yesterday, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [combined positive score (CPS) ≥ 1] as determined by an FDA-approved test, as a single agent ...
Could A Telehealth Program Enhance Geriatric Cancer Care?
A telehealth-based care program may improve daily functioning, mood, disease understanding, and quality of life among older adults with cancer, according to a recent study published by Bergerot et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods and Results...
FDA Approves Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer
On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved mitomycin intravesical solution (Zusduri) for adult patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. Mitomycin intravesical solution is a reverse thermal hydrogel formulation of mitomycin...
CancerCare Survey Reveals How Insurance Red Tape Impacts Cancer Treatment Delays
Findings from a first-of-its-kind national survey are included in “The Health Insurance Maze: How Cancer Patients Get Lost in the Red Tape of Utilization Management,” a new report from CancerCare which details the impact that prior authorization requirement and coverage stoppages have on patients...
Nomogram Model May Predict DVT Risk in Patients With Ovarian Cancer
Researchers have developed a nomogram prediction model for the development of deep vein thrombosis (DVT) in patients with epithelial ovarian cancer, according to study results published in Menopause, the journal of The Menopause Society. A number of significant independent risk factors for DVT...
FDA Approves Taletrectinib for ROS1-Positive Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved the oral next-generation ROS1 tyrosine kinase inhibitor (TKI) talectrectinib (Ibtrozi) for the treatment of adults with ROS1-positive locally advanced or metastatic non–small cell lung cancer (NSCLC). Investigators reported that the agent has ...
Study Reports Increasing Incidence Rates of Appendiceal Adenocarcinoma in Those Born After 1945
A recent study published in the Annals of Internal Medicine1 estimated incidence rates of appendiceal adenocarcinoma across birth cohorts in the United States. Andreana N. Holowatyj, PhD, MSCI, of Vanderbilt-Ingram Cancer Center, Nashville, and colleagues observed a sharp increase in incidence...
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared disease-free survival outcomes of adjuvant cemiplimab vs placebo in patients with high-risk cutaneous squamous cell carcinoma. Study Details In the trial, 415...
Self-Collection Kit Mailings May Increase Cervical Cancer Screening Rates in Underserved Settings
Mail-in self-collection kits for human papillomavirus (HPV) were found to be effective at increasing cervical cancer screening rates compared with standard telephone reminders alone in a safety-net health-care setting, according to results from the PRESTIS trial published in JAMA Internal Medicine. ...
Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests
Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...
AACR Statement on Former President Joseph Biden’s Cancer Diagnosis
The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family as...
I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer
More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...
MD Anderson Names Jeffrey E. Lee, MD, Chief Medical Executive
The University of Texas MD Anderson Cancer Center announced that Jeffrey E. Lee, MD, an internationally regarded leader in the field of oncology, has been appointed Chief Medical Executive (CME). Prior to his appointment, Dr. Lee served as CME ad interim. Assuming the role of CME is the...
Use of Bispecific Antibody in Older Patients With Relapsed or Refractory Multiple Myeloma
Although treatment with the bispecific antibody teclistamab was approved for patients with relapsed or refractory multiple myeloma, based on the MajesTEC-1 study results, only 15% of patients in the phase I/II trial were aged 75 or older. To learn more about the safety and efficacy of this agent in ...
ESTRO 2025: Major Advances in Radiotherapy for Anal and Rectal Cancers
In May in Vienna, five studies presented at ESTRO (European Society for Radiotherapy and Oncology) 2025 showcased how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations ...
Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women
The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...
ASTRO Survey Data Illustrate Impact of Continued Medicare Cuts on Cancer Care
Recent national survey data from the American Society for Radiation Oncology (ASTRO) have shown that further cuts to Medicare reimbursement for radiation therapy would increase patient wait times for cancer treatment and force clinic downsizing. Nearly all (96%) of the 675 physicians responding to...
Retifanlimab-dlwr Approved for Anal Cancer in Combination With Carboplatin Plus Paclitaxel and as a Single Agent
The U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. The FDA also...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data...
